Newsroom

All News
  • All News
  • In the News
  • Press Releases
  • Publications
  • Events
Immunexpress.com

Immunexpress Presents Data Supporting SeptiCyte® RAPID for COVID-19 Patient Triage as a Late-Breaking Abstract at ECCMID 2021

SEATTLE, July 9, 2021 – Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a late-breaking presentation, titled “Use of SeptiCyte RAPID to assess the risk of ICU admission in COVID-19 patients” (ID#4984), demonstrating the performance of SeptiCyte® RAPID in triaging COVID-19 patients...
ECCMID

Use of SeptiCyte® RAPID Assay to Assess the Risk of ICU admission in COVID-19 Patients

ECCMID_P04984_REVIEW_21June2021
MedTech Gurus

Finding The Product- Market Fit, with Rollie Carlson Ph.D. CEO of Immunexpress

Gurus, why should you have your engineers and researchers out in the field? How can they get a good product-market fit? What is the NOT INVENTED HERE factor and why should you avoid it? Dr. Carlson discusses this and more. Listen in as he provides further evidence that perfect should...
SA_logo-V_CMYK

The Role of a Host Response Test in Early Identification and Appropriate Intervention for Sepsis

Dr. Roy Davis provides an overview of the current challenges of sepsis diagnosis and management, specifically related to early identification and appropriate intervention. He describes how the host immune response can be leveraged by including a gene expression assay as part of the Sepsis Clinical Toolset. The proposed role for...
SCCM 2021

SeptiCyte® RAPID in Sepsis Cases with Malignancies or Treated with Anitneoplastics/Immunosuppressants

A study showing the performance of SeptiCyte RAPID in patients with malignancies and/or on anti-neoplastic or corticosteroid therapies. IMM-009-SCCM-04-01-SC
Immunexpress.com

Immunexpress Presents Data Further Demonstrating SeptiCyte® RAPID Performance at the Society of Critical Care Medicine’s 50th Annual Critical Care Congress

Data Demonstrate the Performance of SeptiCyte® RAPID is Unaltered by Patient Malignancy or Treatment with Anti-neoplastics or Immunosuppressants Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a research snapshot presentation of clinical data demonstrating the performance of SeptiCyte® RAPID in adult and pediatric...
Immunexpress.com

Immunexpress to Present SeptiCyte® RAPID Performance Data at the 50th Critical Care Congress

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the publication of an abstract for a research snapshot presentation to be presented as part of the Society of Critical Care Medicine's (SCCM) 50th Annual Critical Care Congress being held virtually Jan. 31 through Feb....
scientia-blue

A Fully Integrated Diagnostic Test to Discriminate Sepsis from Infection-Negative Systemic Inflammation

Sepsis is a serious medical condition that manifests with a dysregulated immune response to an infection in the bloodstream, and is a major cause of morbidity and mortality worldwide. Many non-infectious conditions can lead to a state of hyper-inflammation known as the systemic inflammatory response syndrome (SIRS), which clinically can...
MedTech Insight

Molecular Dx Company Biocartis ‘At Inflection Point’ As It Eyes Infectious Disease Market

Executive Summary Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.
Immunexpress.com

Immunexpress to Present SeptiCyte® RAPID Data at the Association for Molecular Pathology Annual Meeting

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced further SeptiCyte® RAPID data demonstrating performance, reproducibility and identification of fungal infections, in two poster presentations at the Association for Molecular Pathology (AMP) 2020 Annual Meeting & Expo on Nov. 16-20.   “Our SeptiCyte®...
AMP2020

Comparison of a Cartridge-Based Host Gene Expressions Test to a Manual Method for Use in the Diagnosis of Sepsis

SeptiCyte® RAPID test is a rapid, repeatable, reproducible, near-patient, immune-response sepsis diagnostic, providing accurate results in ~ 1 hr to differentiate sepsis from SIRS
AMP2020

In Silico Performance of a Rapid Sepsis Test in Patients with Candidemia

SeptiCyte® RAPID differentiated patients with candidemia from those with INSI/SIRS, not infected and healthy subjects  

If you are a member of the media, please contact:

Maggie Beller
Russo Partners
(646) 942-5631
maggie.beller@russopartnersllc.com